{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:37:13Z","timestamp":1793824633872,"version":"4.6.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2026NSFSC0667"],"award-info":[{"award-number":["2026NSFSC0667"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00978-0","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T02:53:28Z","timestamp":1786071208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer"],"prefix":"10.1186","volume":"14","author":[{"given":"Ru-yan","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-fan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Qing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-jie","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2942-0004","authenticated-orcid":false,"given":"Hao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-wu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"6","key":"978_CR1","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1245\/s10434-025-17062-w","volume":"32","author":"M Boubaddi","year":"2025","unstructured":"Boubaddi M, Rossi J, Marichez A, et al. Preoperative Prognostic Factors in Resectable Pancreatic Cancer: State of the Art and Prospects [J]. Ann Surg Oncol. 2025;32(6):4117\u201327.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"978_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel EM, Brand RE, Goggins M. Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention [J]. Gastroenterology. 2023;164(5):752\u201365.","journal-title":"Gastroenterology"},{"issue":"8","key":"978_CR3","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Di Pasca M, et al. Pancreatic cancer: Advances and challenges [J]. Cell. 2023;186(8):1729\u201354.","journal-title":"Cell"},{"key":"978_CR4","unstructured":"Zhou K, Liu Y, Tang C, et al. Pancreatic cancer: pathogenesis and clinical studies [J]. MedComm. 2020;20256(4):e70162."},{"issue":"3","key":"978_CR5","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.7150\/thno.64805","volume":"12","author":"L Liu","year":"2022","unstructured":"Liu L, Kshirsagar PG, Gautam SK, et al. Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies [J]. Theranostics. 2022;12(3):1030\u201360.","journal-title":"Theranostics"},{"issue":"24","key":"978_CR6","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity [J]. Proc Natl Acad Sci U S A. 1989;86(24):10024\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"978_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2643-3230.BCD-24-0317","volume":"7","author":"X Zhang","year":"2026","unstructured":"Zhang X, Wang J, Wang N, et al. Long-term Therapy Outcomes of CD19\/22 CAR T Cell Alone or with Autologous Stem Cell Transplantation for Relapsed\/Refractory DLBCL [J]. Blood Cancer Discov. 2026;7(1):142\u201353.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"978_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, et al. CAR-T cell therapy for cancer: current challenges and future directions [J]. Signal Transduct Target Ther. 2025;10(1):210.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"978_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/imr.13273","volume":"320","author":"MN Kronig","year":"2023","unstructured":"Kronig MN, Wehrli M, Salas-Benito D, et al. Hurdles race for CAR T-cell therapy in digestive tract cancer [J]. Immunol Rev. 2023;320(1):100\u201319.","journal-title":"Immunol Rev"},{"key":"978_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jare.2024.01.014","volume":"67","author":"HY Tang","year":"2025","unstructured":"Tang HY, Cao YZ, Zhou YW, et al. The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer [J]. J Adv Res. 2025;67:253\u201367.","journal-title":"J Adv Res"},{"issue":"5","key":"978_CR11","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, et al. From concept to cure: The evolution of CAR-T cell therapy [J]. Mol Ther. 2025;33(5):2123\u201340.","journal-title":"Mol Ther"},{"key":"978_CR12","doi-asserted-by":"publisher","first-page":"1519671","DOI":"10.3389\/fimmu.2024.1519671","volume":"15","author":"Y Kong","year":"2024","unstructured":"Kong Y, Li J, Zhao X, et al. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity [J]. Front Immunol. 2024;15:1519671.","journal-title":"Front Immunol"},{"key":"978_CR13","doi-asserted-by":"crossref","unstructured":"Uscanga-Palomeque A C, Ch\u00e1vez-Escamilla A K, Alvizo-B\u00e1ez C A, et al. CAR-T cell therapy: from the shop to cancer therapy [J]. Int J Mol Sci, 2023;24(21).","DOI":"10.3390\/ijms242115688"},{"key":"978_CR14","first-page":"95","volume":"15","author":"ER Hawkins","year":"2021","unstructured":"Hawkins ER, D\u2019souza RR, Klampatsa A. Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy [J]. Biologics. 2021;15:95\u2013105.","journal-title":"Biologics"},{"key":"978_CR15","doi-asserted-by":"publisher","first-page":"1288383","DOI":"10.3389\/fonc.2023.1288383","volume":"13","author":"R Chen","year":"2023","unstructured":"Chen R, Chen L, Wang C, et al. CAR-T treatment for cancer: prospects and challenges [J]. Front Oncol. 2023;13:1288383.","journal-title":"Front Oncol"},{"issue":"4","key":"978_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/BS9.0000000000000173","volume":"5","author":"JY Wang","year":"2023","unstructured":"Wang JY, Wang L. CAR-T cell therapy: Where are we now, and where are we heading? [J]. Blood Sci. 2023;5(4):237\u201348.","journal-title":"Blood Sci"},{"key":"978_CR17","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui TA, Mei H, Sang R, et al. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment [J]. EBioMedicine. 2024;106:105266.","journal-title":"EBioMedicine"},{"issue":"22","key":"978_CR18","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review [J]. JAMA. 2024;332(22):1924\u201335.","journal-title":"JAMA"},{"issue":"1","key":"978_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies [J]. J Hematol Oncol. 2024;17(1):105.","journal-title":"J Hematol Oncol"},{"issue":"31","key":"978_CR20","doi-asserted-by":"publisher","first-page":"e2403002121","DOI":"10.1073\/pnas.2403002121","volume":"121","author":"U Amit","year":"2024","unstructured":"Amit U, Uslu U, Verginadis II, et al. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer [J]. Proc Natl Acad Sci U S A. 2024;121(31):e2403002121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"978_CR21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1158\/0008-5472.CAN-22-2245","volume":"83","author":"KR Hagel","year":"2023","unstructured":"Hagel KR, Arafeh R, Gang S, et al. Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer [J]. Cancer Res. 2023;83(4):613\u201325.","journal-title":"Cancer Res"},{"issue":"2","key":"978_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neo.2021.12.005","volume":"24","author":"HH Lee","year":"2022","unstructured":"Lee HH, Kim I, Kim UK, et al. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models [J]. Neoplasia. 2022;24(2):98\u2013108.","journal-title":"Neoplasia"},{"issue":"19","key":"978_CR23","doi-asserted-by":"publisher","first-page":"e2202439119","DOI":"10.1073\/pnas.2202439119","volume":"119","author":"X Liu","year":"2022","unstructured":"Liu X, Onda M, Watson N, et al. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin [J]. Proc Natl Acad Sci U S A. 2022;119(19):e2202439119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"978_CR24","doi-asserted-by":"publisher","first-page":"1524899","DOI":"10.3389\/fimmu.2025.1524899","volume":"16","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Yang Y, Yue L, et al. Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer [J]. Front Immunol. 2025;16:1524899.","journal-title":"Front Immunol"},{"key":"978_CR25","doi-asserted-by":"crossref","unstructured":"Stock S, Benmebarek MR, Kluever AK, et al. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors [J]. J Immunother Cancer. 2022;10(7).","DOI":"10.1136\/jitc-2022-005054"},{"key":"978_CR26","doi-asserted-by":"crossref","unstructured":"Li D, Liang T, Hutchins LE, et al. rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors [J]. J Immunother Cancer. 2024;12(7).","DOI":"10.1136\/jitc-2024-008989"},{"issue":"4","key":"978_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jcyt.2024.01.011","volume":"26","author":"GJ Chu","year":"2024","unstructured":"Chu GJ, Bailey CG, Nagarajah R, et al. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity [J]. Cytotherapy. 2024;26(4):325\u201333.","journal-title":"Cytotherapy"},{"issue":"4","key":"978_CR28","doi-asserted-by":"publisher","first-page":"e2317283121","DOI":"10.1073\/pnas.2317283121","volume":"121","author":"XF Liu","year":"2024","unstructured":"Liu XF, Onda M, Schlomer J, et al. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope [J]. Proc Natl Acad Sci U S A. 2024;121(4):e2317283121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"978_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00262-025-04039-7","volume":"74","author":"MA Aboalela","year":"2025","unstructured":"Aboalela MA, Abdelmoneim M, Matsumura S, et al. Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression [J]. Cancer Immunol Immunother. 2025;74(7):202.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"978_CR30","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","volume":"30","author":"M Wehrli","year":"2024","unstructured":"Wehrli M, Guinn S, Birocchi F, et al. Mesothelin CAR T Cells Secreting Anti-FAP\/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma [J]. Clin Cancer Res. 2024;30(9):1859\u201377.","journal-title":"Clin Cancer Res"},{"key":"978_CR31","doi-asserted-by":"crossref","unstructured":"Wang Y, Fang X, Li M, et al. Mesothelin CAR-T cells secreting PD-L1 blocking scFv for pancreatic cancer treatment [J]. Cancer Genet. 2022;268\u20139:103\u201310.","DOI":"10.1016\/j.cancergen.2022.10.003"},{"issue":"6","key":"978_CR32","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1016\/j.ymthe.2025.01.012","volume":"33","author":"G Zhong","year":"2025","unstructured":"Zhong G, Zhang X, Zhao R, et al. The high efficacy of claudin18.2-targeted CAR-T cell therapy in advanced pancreatic cancer with an antibody-dependent safety strategy [J]. Mol Ther. 2025;33(6):2778\u201388.","journal-title":"Mol Ther"},{"issue":"11","key":"978_CR33","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","volume":"31","author":"R Sun","year":"2023","unstructured":"Sun R, Sun Y, Wu C, et al. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer [J]. Mol Ther. 2023;31(11):3193\u2013209.","journal-title":"Mol Ther"},{"issue":"1","key":"978_CR34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-023-01491-9","volume":"16","author":"C Qi","year":"2023","unstructured":"Qi C, Xie T, Zhou J, et al. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer [J]. J Hematol Oncol. 2023;16(1):102.","journal-title":"J Hematol Oncol"},{"key":"978_CR35","doi-asserted-by":"publisher","first-page":"1325860","DOI":"10.3389\/fimmu.2024.1325860","volume":"15","author":"G Zhong","year":"2024","unstructured":"Zhong G, Zhang X, Guo Z, et al. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report [J]. Front Immunol. 2024;15:1325860.","journal-title":"Front Immunol"},{"issue":"1","key":"978_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12967-023-04080-z","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu Y, Sun Y, Wang P, et al. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer [J]. J Transl Med. 2023;21(1):255.","journal-title":"J Transl Med"},{"issue":"5","key":"978_CR37","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1158\/1535-7163.MCT-25-0171","volume":"25","author":"S Du","year":"2026","unstructured":"Du S, Zhang Y, Hao R, et al. Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity [J]. Mol Cancer Ther. 2026;25(5):701\u201316.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"978_CR38","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.21037\/jgo-2025-564","volume":"16","author":"X Zhang","year":"2025","unstructured":"Zhang X, Shi H, Qiu L, et al. Local radiotherapy polarized tumor-associated macrophages enhance the efficacy of Claudin18.2-targeted CAR-T therapy in pancreatic cancer [J]. J Gastrointest Oncol. 2025;16(4):1682\u201398.","journal-title":"J Gastrointest Oncol"},{"key":"978_CR39","doi-asserted-by":"crossref","unstructured":"Li K, Huo Q, Minami K, et al. Exploring the Tumor-Suppressing Potential of PSCA in Pancreatic Ductal Adenocarcinoma [J]. Cancers (Basel). 2023;15(20).","DOI":"10.3390\/cancers15204917"},{"key":"978_CR40","doi-asserted-by":"crossref","unstructured":"Dai Z, Zhu Z, Li Z, et al. Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice [J]. J Clin Invest. 2025;135(8).","DOI":"10.1172\/JCI179014"},{"key":"978_CR41","doi-asserted-by":"publisher","first-page":"1618404","DOI":"10.3389\/fimmu.2025.1618404","volume":"16","author":"AG Torres Chavez","year":"2025","unstructured":"Torres Chavez AG, Mckenna MK, Gupta A, et al. IL-7 armed binary CAR T cell strategy to augment potency against solid tumors [J]. Front Immunol. 2025;16:1618404.","journal-title":"Front Immunol"},{"key":"978_CR42","doi-asserted-by":"crossref","unstructured":"Li Z, Liu N, Shah Z, et al. Comparative efficacy and safety of PSCA CAR-engineered V\u03b41 \u03b3\u03b4 T cells for immunotherapy of pancreatic cancer [J]. J Immunother Cancer. 2025;13(9).","DOI":"10.1136\/jitc-2025-011890"},{"issue":"7","key":"978_CR43","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.ymthe.2021.02.024","volume":"29","author":"JP Murad","year":"2021","unstructured":"Murad JP, Tilakawardane D, Park AK, et al. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity [J]. Mol Ther. 2021;29(7):2335\u201349.","journal-title":"Mol Ther"},{"issue":"24","key":"978_CR44","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.1039\/D4TB00091A","volume":"12","author":"Y Yao","year":"2024","unstructured":"Yao Y, Zheng Y, Wu M, et al. CD133-targeted multifunctional nanomicelles for dual-modality imaging and synergistic high-intensity focus ultrasound (HIFU) ablation on pancreatic cancer in nude mice [J]. J Mater Chem B. 2024;12(24):5884\u201397.","journal-title":"J Mater Chem B"},{"key":"978_CR45","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.2147\/IJN.S391382","volume":"18","author":"R Wang","year":"2023","unstructured":"Wang R, Yao Y, Gao Y, et al. CD133-Targeted Hybrid Nanovesicles for Fluorescent\/Ultrasonic Imaging-Guided HIFU Pancreatic Cancer Therapy [J]. Int J Nanomed. 2023;18:2539\u201352.","journal-title":"Int J Nanomed"},{"key":"978_CR46","doi-asserted-by":"crossref","unstructured":"Xiong T, Wang G, Yu P, et al. CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors [J]. J Clin Invest. 2025;135(15).","DOI":"10.1172\/JCI189920"},{"issue":"1","key":"978_CR47","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1186\/s12967-024-05462-7","volume":"22","author":"T Deng","year":"2024","unstructured":"Deng T, Deng Y, Tsao ST, et al. Rapidly-manufactured CD276 CAR-T cells exhibit enhanced persistence and efficacy in pancreatic cancer [J]. J Transl Med. 2024;22(1):633.","journal-title":"J Transl Med"},{"issue":"3","key":"978_CR48","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11684-021-0901-2","volume":"16","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success? [J]. Front Med. 2022;16(3):322\u201338.","journal-title":"Front Med"},{"issue":"9","key":"978_CR49","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1016\/j.ymthe.2022.07.006","volume":"30","author":"Z Raglow","year":"2022","unstructured":"Raglow Z, Mckenna MK, Bonifant CL, et al. Targeting glycans for CAR therapy: The advent of sweet CARs [J]. Mol Ther. 2022;30(9):2881\u201390.","journal-title":"Mol Ther"},{"issue":"6","key":"978_CR50","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","volume":"44","author":"JR POSEY A D","year":"2016","unstructured":"Posey A D Jr, Schwab R D, Boesteanu A C, et al. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma [J]. Immunity. 2016;44(6):1444\u201354.","journal-title":"Immunity"},{"issue":"1","key":"978_CR51","doi-asserted-by":"publisher","first-page":"11246","DOI":"10.1038\/s41467-025-66102-2","volume":"16","author":"S Park","year":"2025","unstructured":"Park S, Ho CE, Darnell EP, et al. Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer [J]. Nat Commun. 2025;16(1):11246.","journal-title":"Nat Commun"},{"issue":"1","key":"978_CR52","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1038\/s41467-022-31035-7","volume":"13","author":"A Heard","year":"2022","unstructured":"Heard A, Landmann JH, Hansen AR, et al. Antigen glycosylation regulates efficacy of CAR T cells targeting CD19 [J]. Nat Commun. 2022;13(1):3367.","journal-title":"Nat Commun"},{"issue":"11","key":"978_CR53","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases [J]. Nat Biotechnol. 2024;42(11):1693\u2013704.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"978_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-023-01467-9","volume":"16","author":"J Fan","year":"2023","unstructured":"Fan J, Yu Y, Yan L, et al. GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer [J]. J Hematol Oncol. 2023;16(1):77.","journal-title":"J Hematol Oncol"},{"key":"978_CR55","doi-asserted-by":"crossref","unstructured":"Li N, Quan A, Li D, et al. The IgG4 hinge with CD28 transmembrane domain improves V(H)H-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer [J]. Nat Commun. 2023;14(1):1986.","DOI":"10.1038\/s41467-023-37616-4"},{"issue":"10","key":"978_CR56","doi-asserted-by":"publisher","first-page":"100804","DOI":"10.1016\/j.medj.2025.100804","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Li Z, Zhu Y, et al. Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells [J]. Med. 2025;6(10):100804.","journal-title":"Med"},{"issue":"5","key":"978_CR57","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41596-024-01077-w","volume":"20","author":"YR Li","year":"2025","unstructured":"Li YR, Zhou K, Lee D, et al. Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture [J]. Nat Protoc. 2025;20(5):1352\u201388.","journal-title":"Nat Protoc"},{"issue":"1","key":"978_CR58","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","volume":"10","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, et al. Nanobody-based CAR-T cells for cancer immunotherapy [J]. Biomark Res. 2022;10(1):24.","journal-title":"Biomark Res"},{"issue":"1","key":"978_CR59","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/s12935-021-02151-z","volume":"21","author":"H Wang","year":"2021","unstructured":"Wang H, Wang L, Li Y, et al. Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells [J]. Cancer Cell Int. 2021;21(1):450.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"978_CR60","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1186\/s12967-024-05461-8","volume":"22","author":"P Safarzadeh Kozani","year":"2024","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Humanization of the antigen-recognition domain does not impinge on the antigen-binding, cytokine secretion, and antitumor reactivity of humanized nanobody-based CD19-redirected CAR-T cells [J]. J Transl Med. 2024;22(1):679.","journal-title":"J Transl Med"},{"issue":"10","key":"978_CR61","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1038\/s41375-021-01269-3","volume":"35","author":"L Han","year":"2021","unstructured":"Han L, Zhang JS, Zhou J, et al. Single VHH-directed BCMA CAR-T cells cause remission of relapsed\/refractory multiple myeloma [J]. Leukemia. 2021;35(10):3002\u20136.","journal-title":"Leukemia"},{"issue":"9","key":"978_CR62","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.ccell.2025.06.021","volume":"43","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ling L, Murad R, et al. Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer [J]. Cancer Cell. 2025;43(9):1677\u2013e9615.","journal-title":"Cancer Cell"},{"key":"978_CR63","doi-asserted-by":"crossref","unstructured":"Shinkawa T, Ohuchida K, Nakamura M. Heterogeneity of Cancer-Associated Fibroblasts and the Tumor Immune Microenvironment in Pancreatic Cancer [J]. Cancers (Basel). 2022;14(16).","DOI":"10.3390\/cancers14163994"},{"key":"978_CR64","doi-asserted-by":"crossref","unstructured":"Di Federico A, Mosca M, Pagani R, et al. Immunotherapy in pancreatic cancer: Why do we keep failing? a focus on tumor immune microenvironment, predictive biomarkers and treatment outcomes [J]. Cancers (Basel). 2022;14(10).","DOI":"10.3390\/cancers14102429"},{"issue":"1","key":"978_CR65","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s43556-024-00233-8","volume":"5","author":"K Lv","year":"2024","unstructured":"Lv K, He T. Cancer-associated fibroblasts: heterogeneity, tumorigenicity and therapeutic targets [J]. Mol Biomed. 2024;5(1):70.","journal-title":"Mol Biomed"},{"issue":"8082","key":"978_CR66","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41586-025-09303-5","volume":"645","author":"J Heide","year":"2025","unstructured":"Heide J, Bilecz AJ, Patnaik S, et al. NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity [J]. Nature. 2025;645(8082):1051\u20139.","journal-title":"Nature"},{"key":"978_CR67","doi-asserted-by":"publisher","first-page":"1582305","DOI":"10.3389\/fimmu.2025.1582305","volume":"16","author":"D Pan","year":"2025","unstructured":"Pan D, Li X, Qiao X, et al. Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets [J]. Front Immunol. 2025;16:1582305.","journal-title":"Front Immunol"},{"key":"978_CR68","doi-asserted-by":"publisher","first-page":"1166860","DOI":"10.3389\/fonc.2023.1166860","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Xiang S, Pan W, et al. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective [J]. Front Oncol. 2023;13:1166860.","journal-title":"Front Oncol"},{"issue":"6","key":"978_CR69","doi-asserted-by":"publisher","first-page":"152411","DOI":"10.1016\/j.seminoncol.2025.152411","volume":"52","author":"DA Guirguis","year":"2025","unstructured":"Guirguis DA, Hasan F, Morris N, et al. Tumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer [J]. Semin Oncol. 2025;52(6):152411.","journal-title":"Semin Oncol"},{"key":"978_CR70","doi-asserted-by":"publisher","first-page":"1782960","DOI":"10.3389\/fimmu.2026.1782960","volume":"17","author":"J Yan","year":"2026","unstructured":"Yan J, Ou H, Wang S, et al. Overcoming multidimensional immunotherapy resistance in PDAC: from microenvironment to clinic [J]. Front Immunol. 2026;17:1782960.","journal-title":"Front Immunol"},{"issue":"Pt 2","key":"978_CR71","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2022.08.009","volume":"86","author":"X Li","year":"2022","unstructured":"Li X, Gulati M, Larson AC, et al. Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert [J]. Semin Cancer Biol. 2022;86(Pt 2):14\u201327.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"978_CR72","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1158\/2159-8290.CD-23-1361","volume":"14","author":"X Liu","year":"2024","unstructured":"Liu X, Sells BE, Denardo DG. RIPping off Pancreas Cancer\u2019s Blockage of Immune Surveillance [J]. Cancer Discov. 2024;14(2):208\u201310.","journal-title":"Cancer Discov"},{"issue":"1","key":"978_CR73","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/gutjnl-2022-327927","volume":"73","author":"M Canel","year":"2023","unstructured":"Canel M, S\u0142awi\u0144ska AD, Lonergan DW, et al. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer [J]. Gut. 2023;73(1):131\u201355.","journal-title":"Gut"},{"key":"978_CR74","doi-asserted-by":"crossref","unstructured":"Safa A, Vruzhaj I, Gambirasi M, et al. Antigenic dark matter: unexplored post-translational modifications of tumor-associated and tumor-specific antigens in pancreatic cancer [J]. Cancers (Basel), 2025;17(21).","DOI":"10.3390\/cancers17213506"},{"key":"978_CR75","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/bs.apcsb.2024.10.008","volume":"144","author":"K Baghel","year":"2025","unstructured":"Baghel K, Mehrotra S, Prajapati VK. Revolutionizing pancreatic cancer treatment with CAR-T therapy [J]. Adv Protein Chem Struct Biol. 2025;144:331\u201353.","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"11","key":"978_CR76","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1158\/2326-6066.CIR-22-0115","volume":"10","author":"P Bajgain","year":"2022","unstructured":"Bajgain P, Torres Chavez AG, Balasubramanian K, et al. Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors [J]. Cancer Immunol Res. 2022;10(11):1370\u201385.","journal-title":"Cancer Immunol Res"},{"issue":"22","key":"978_CR77","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1111\/bph.16505","volume":"181","author":"S Ruixin","year":"2024","unstructured":"Ruixin S, Yifan L, Yansha S, et al. Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer [J]. Br J Pharmacol. 2024;181(22):4628\u201346.","journal-title":"Br J Pharmacol"},{"key":"978_CR78","doi-asserted-by":"crossref","unstructured":"Senz AM, Metzger P, Rubens RK, et al. P06.05 IDO1-deleted CAR T cells show improved therapeutic efficacy in murine pancreatic cancer models [J]. J Immunother Cancer, 2020;8(Suppl 2).","DOI":"10.1136\/jitc-2020-ITOC7.84"},{"issue":"9","key":"978_CR79","doi-asserted-by":"publisher","first-page":"102301","DOI":"10.1016\/j.xcrm.2025.102301","volume":"6","author":"MA Aznar","year":"2025","unstructured":"Aznar MA, Good CR, Barber-Rotenberg JS, et al. Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer [J]. Cell Rep Med. 2025;6(9):102301.","journal-title":"Cell Rep Med"},{"key":"978_CR80","doi-asserted-by":"crossref","unstructured":"Nakagawara K, Ando M, Srirat T, et al. NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors [J]. J Immunother Cancer, 2024, 12(8).","DOI":"10.1136\/jitc-2023-008665"},{"key":"978_CR81","doi-asserted-by":"crossref","unstructured":"Czaplicka A, Lachota M, P\u0105czek L, et al. Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence [J]. Cells, 2024, 13(1).","DOI":"10.3390\/cells13010101"},{"issue":"10","key":"978_CR82","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","volume":"22","author":"Y Liu","year":"2020","unstructured":"Liu Y, Guo Y, Wu Z, et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial [J]. Cytotherapy. 2020;22(10):573\u201380.","journal-title":"Cytotherapy"},{"issue":"21","key":"978_CR83","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1200\/JCO.23.02314","volume":"42","author":"C Qi","year":"2024","unstructured":"Qi C, Zhang P, Liu C, et al. Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials [J]. J Clin Oncol. 2024;42(21):2565\u201377.","journal-title":"J Clin Oncol"},{"issue":"1","key":"978_CR84","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Todd L, Huang L, et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors [J]. Nat Commun. 2023;14(1):5110.","journal-title":"Nat Commun"},{"key":"978_CR85","doi-asserted-by":"crossref","unstructured":"Senz AM, Cadilha BL, Teppert J, et al. RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinoma [J]. J Immunother Cancer. 2026;14(1).","DOI":"10.1136\/jitc-2025-013282"},{"issue":"47","key":"978_CR86","doi-asserted-by":"publisher","first-page":"e2517786122","DOI":"10.1073\/pnas.2517786122","volume":"122","author":"YR Li","year":"2025","unstructured":"Li YR, Shen X, Zhu E, et al. Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected CAR-NKT cells [J]. Proc Natl Acad Sci U S A. 2025;122(47):e2517786122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"978_CR87","doi-asserted-by":"publisher","first-page":"1643941","DOI":"10.3389\/fimmu.2025.1643941","volume":"16","author":"DD Yang","year":"2025","unstructured":"Yang DD, Macmorland W, Arnold JN. Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment [J]. Front Immunol. 2025;16:1643941.","journal-title":"Front Immunol"},{"key":"978_CR88","doi-asserted-by":"publisher","first-page":"1545270","DOI":"10.3389\/fimmu.2025.1545270","volume":"16","author":"M Shirzadian","year":"2025","unstructured":"Shirzadian M, Moori S, Rabbani R, et al. SynNotch CAR-T cell, when synthetic biology and immunology meet again [J]. Front Immunol. 2025;16:1545270.","journal-title":"Front Immunol"},{"issue":"8","key":"978_CR89","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41565-025-01924-1","volume":"20","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Li Q, Qu C, et al. A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer [J]. Nat Nanotechnol. 2025;20(8):1131\u201341.","journal-title":"Nat Nanotechnol"},{"issue":"8Supplement1","key":"978_CR90","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1538-7445.AM2025-3129","volume":"85","author":"K Bajbouj","year":"2025","unstructured":"Bajbouj K, Xiao Z, Hopper LA, et al. Abstract 3129: Fibroblast activation protein directed CAR T cells engineered in situ using targeted lipid nanoparticles inhibit progression of pancreatic ductal adenocarcinoma [J]. Cancer Res. 2025;85(8Supplement1):3129.","journal-title":"Cancer Res"},{"issue":"10","key":"978_CR91","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","volume":"25","author":"YR Li","year":"2025","unstructured":"Li YR, Zhu Y, Halladay T, et al. In vivo CAR engineering for immunotherapy [J]. Nat Rev Immunol. 2025;25(10):725\u201344.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"978_CR92","doi-asserted-by":"publisher","first-page":"102337","DOI":"10.1016\/j.xcrm.2025.102337","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Yang L. From bench to body: In vivo CAR engineering in the clinic [J]. Cell Rep Med. 2025;6(11):102337.","journal-title":"Cell Rep Med"},{"issue":"4","key":"978_CR93","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/XCS.0000000000000964","volume":"238","author":"C Chen","year":"2024","unstructured":"Chen C, Park AK, Monroy I, et al. Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor [J]. J Am Coll Surg. 2024;238(4):436\u201347.","journal-title":"J Am Coll Surg"},{"key":"978_CR94","doi-asserted-by":"crossref","unstructured":"Purl MC, Shick A, Karimzadeh M, et al. 268 Regional B7-H3 CAR cell therapy and liver-directed radiation for pancreatic cancer liver metastases [J]. J Immunother Cancer. 2025;13(Suppl 2).","DOI":"10.1136\/jitc-2025-SITC2025.0268"},{"key":"978_CR95","doi-asserted-by":"publisher","first-page":"1764452","DOI":"10.3389\/fimmu.2026.1764452","volume":"17","author":"S Shen","year":"2026","unstructured":"Shen S, Ruan Z, Jiang B, et al. CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors [J]. Front Immunol. 2026;17:1764452.","journal-title":"Front Immunol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00978-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00978-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00978-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:05:00Z","timestamp":1788278700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00978-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["978"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00978-0","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"108"}}